ClinicalTrials.gg
CompletedNCT04169386Updated Feb 28, 2025

A Study of PCSK9 Inhibitor AK102 in Healthy Subjects

A Phase 1 interventional study of AK102 and Placebo in Hypercholesterolaemia, sponsored by Akeso. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by Akeso · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled May 2018, registered Nov 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Hypercholesterolemia with a site in China — 10 open to participants now, 17 under way, 10 of them phase 3. Hypercholesterolemia · China.

Enrollment
49th of 53
32 · median 207
Started
2018
with 1 other
Phase 1
12 of 59
2 open now
Registered
22nd of 59
by date
Lead sponsor
3 of 59
Akeso

Among the 59 studies in Hypercholesterolemia with a site in China, this one is the 49th largest by enrollment of the 53 interventional ones that give a count, is one of 2 that started in 2018, is one of 12 in phase 1, and was the 22nd registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

10 of the 59 studies in Hypercholesterolemia with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Hypercholesterolemia with a site in China, or all of them as a file.
02

Study summary

This is a first-in-human,randomized, double-blind, placebo-controlled, single dose escalation, phase 1 study to evaluate the safety, tolerability, PK/PD and immunogenicity of AK102 administered subcutaneously in healthy subjects. Subjects will be randomized into 4 planned single dose escalation cohorts or placebo cohort.

03

Conditions studied

  • Hypercholesterolaemia
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed .
  • No abnormalities judged by the principal investigator based on the medical history, physical examination, and routine laboratory evaluations.
  • Low-density lipoprotein cholesterol (LDL-C) level of 70-190 mg/dL (inclusive).
  • (BMI) ≥18 and ≤ 28 kg/m\^2 , body weight >= 50 kg for male or >= 45 kg for female.

Exclusion criteria

Exclusion Criteria:

  • Triglyceride concentration >400 mg/dL (4.5 mmol/L).
  • History of reactions to any substance of the investigation drug or other monoclonal antibodies.
  • Drug or alcohol abuse within 6 months prior to dosing.
  • Blood pressure >140 mmHg (systolic) or > 90 mmHg (diastolic)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    AK102 75mg

    AK102 75mg

    Drug: AK102

  • Experimental
    AK102 150mg

    AK102 150mg

    Drug: AK102

  • Experimental
    AK102 300mg

    AK102 300mg

    Drug: AK102

  • Experimental
    AK102 500mg

    AK102 500mg

    Drug: AK102

  • Placebo comparator
    Placebo

    Matching placebo

    Drug: Placebo

Interventions

  • DrugAK102

    AK102 single dose administered subcutaneously

  • DrugPlacebo

    Placebo single dose administered subcutaneously

06

What researchers measure

Primary outcomes

  1. Incidence of treatment emergent AE

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: From single dose of AK102 through 12 weeks

Secondary outcomes

  1. Pharmacokinetic characteristics of AK102

    Serum concentrations of AK102 at different timepoints before and after AK102 single dose.

    Time frame: over 12 weeks

  2. Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)

    Low-Density Lipoprotein Cholesterol (LDL-C) blood concentrations before and after AK102 single dose.

    Time frame: At different time points from baseline through 12 weeks

  3. Percent Change From Baseline in PCSK9

    PCSK9 blood concentrations before and after AK102 single dose.

    Time frame: At different time points from baseline through 12 weeks

  4. Number of subjects who develop detectable anti-drug antibodies (ADAs)

    The immunogenicity of AK102 will be assessed by summarizing the number of subjects who develop detectable ADAs.

    Time frame: At different time points from baseline through 12 weeks

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Peking, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Nov 2018, 5 months.

Of 41 industry-sponsored phase 1 interventional studies under Hypercholesterolemia, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 5 months is below that.

Counting every sponsor, half of 46 studies reached it within 7 months; a quarter within 2 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2019
First posted
Nov 19, 2019
StartActual
May 23, 2018
Primary completionActual
Nov 22, 2018
CompletionActual
Nov 22, 2018
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04169386
Lead sponsor
Akeso
Collaborators
AD Pharmaceuticals Co., Ltd.
Responsible party
Sponsor
First posted
Nov 19, 2019
Start date
May 23, 2018
Primary completion
Nov 22, 2018
Completion
Nov 22, 2018
Last update
Feb 28, 2025

Study contacts

Rui Chen, MD
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ebronucimab

Start the discussion